Helicobacter pylori Vaccine Development Services

Leveraging deep expertise in gastrointestinal pathogenesis and mucosal immunology, Ace Therapeutics delivers comprehensive H. pylori vaccine development services to address critical challenges in bacterial eradication and gastric protection. Our specialized platform integrates antigen discovery, adjuvant optimization, and mucosal delivery technologies to develop next-generation vaccines.

Advances in H. pylori Vaccine Development

Currently, no Helicobacter pylori vaccine is clinically available, despite decades of research, due to challenges like strain diversity and the need for robust mucosal immunity. However, several promising candidates are in development: subunit vaccines (e.g., UreB/CagA/VacA combinations with novel adjuvants like TLR agonists), mRNA-based vaccines for rapid antigen design, and mucosal vaccines (oral/nasal nanoparticles or bacterial OMVs) to induce gut-specific immunity.

Key Antigen Targets of H. pylori

Types of Hepatitis Virus Vaccine We Can Develop

• Multi-Antigen Subunit Vaccines Our subunit vaccine design platform integrates selected antigenic targets including UreB, CagA, VacA and neutrophil-activating protein (NAP) with next-generation adjuvants such as Toll-like receptor (TLR) agonists to elicit comprehensive immune responses against diverse pathogenic strains. This antigen-adjuvant combination approach enables simultaneous targeting of multiple virulence mechanisms while overcoming strain-specific variability through broad epitope coverage and enhanced immunostimulation.
• mRNA-Based Vaccines We can utilize optimized lipid nanoparticle (LNP) formulations to deliver engineered mRNA sequences encoding key H. pylori antigens, including urease subunit B (UreB) and cytotoxin-associated gene A (CagA) proteins. This innovative approach combines the advantages of rapid antigen design flexibility with potent cellular immunity induction to maximize mucosal immune protection against gastric pathogens.
• Therapeutic Vaccines for Chronic Infection Our therapeutic vaccine platform combines keyH. pylori virulence factors (CagA and VacA) with immune checkpoint modulators to overcome bacterial persistence in chronic infections. This dual-targeting approach simultaneously neutralizes pathogenic mechanisms while reversing H. pylori-induced immune tolerance, offering a promising antibiotic-sparing strategy for complete bacterial eradication and long-term mucosal protection.
• Virus-Like Particle (VLP) Vaccines Our engineered virus-like particle (VLP) platform displays conformationally intact H. pylori antigens, including urease subunit B (UreB), through sophisticated molecular scaffolding techniques that authentically mimic natural pathogen presentation. This biomimetic approach significantly enhances antigen uptake and processing by antigen-presenting cells, resulting in durable, high-affinity antibody responses and robust T-cell memory that collectively provide long-term protection against H. pylori ninfection.
• Live Attenuated/Vectored Vaccines Our vaccine delivery platform harnesses the natural tropism of attenuated Salmonella and adenoviral vectors to efficiently transport H. pylori antigens to intestinal mucosal tissues. These engineered vectors capitalize on their inherent ability to target gut-associated lymphoid tissue (GALT), thereby stimulating potent local and systemic immune responses through enhanced antigen presentation and lymphocyte activation.

Based on our foundational expertise in gastric mucosal immunity and microbial pathogenesis, Ace Therapeutics has established a specialized vaccine development platform that tackles the key obstacles in achieving durable Helicobacter pylorieradication and effective gastric mucosa protection. If you are interested in our services, please do not hesitate to contact us.

Our products and services are for research use only and can not be used for diagnostic or other purposes.